Identifying cancer-related proteins in dogs to improve treatment options
Canine MHC-I genotyping and tumor specific neoantigen determination
['FUNDING_R01'] · UNIVERSITY OF GEORGIA · NIH-11079548
This study is looking at how certain proteins linked to cancer in dogs can help improve cancer treatments, so if you have a dog with cancer, this research could lead to better therapies for them.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF GEORGIA (nih funded) |
| Locations | 1 site (ATHENS, UNITED STATES) |
| Trial ID | NIH-11079548 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding how specific proteins related to cancer in dogs can be identified and used to enhance cancer treatments. By analyzing the genetic makeup of these proteins, researchers aim to predict tumor-specific neoantigens, which are crucial for developing effective immunotherapies. The study utilizes advanced sequencing techniques and computational tools to gather and analyze data from a wide range of dog breeds, ultimately bridging the gap between canine and human cancer treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are pet dogs diagnosed with cancer, particularly those with spontaneous tumors.
Not a fit: Patients who do not have cancer or those whose cancers are not amenable to the specific immunotherapy approaches being investigated may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer therapies for both dogs and humans by improving the understanding of tumor-specific targets.
How similar studies have performed: Previous research has shown promise in using canine models to advance cancer treatment, indicating that this approach could yield significant insights.
Where this research is happening
ATHENS, UNITED STATES
- UNIVERSITY OF GEORGIA — ATHENS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ZHAO, SHAYING — UNIVERSITY OF GEORGIA
- Study coordinator: ZHAO, SHAYING
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Advanced Cancer, anti-cancer immunotherapy, anti-cancer therapy, anticancer immunotherapy